Bayer's Q1 Earnings Surprise Clashes with €2.3 Billion Legal Cash Drain as Key Court Deadlines Loom

Bayer's Q1 operating profit smashed estimates, but legal settlements for glyphosate and PCB lawsuits drove free cash flow to minus €2.32 billion, raising net debt.

Bayer has kicked off 2026 with a ferocious tug-of-war between its operating engine and its legal legacy. The German life-science group smashed first-quarter profit forecasts, yet a torrent of cash headed out the door to settle decades-old lawsuits. The split screen sets the stage for Judith Hartmann, who formally takes over as chief financial officer on June 1, inheriting both an unexpectedly strong business momentum and a balance sheet still bearing the scars of glyphosate and PCB litigation.

Revenue in the opening quarter reached €13.405 billion, up 4.1 percent on a currency- and portfolio-adjusted basis even as adverse exchange rates dented the reported top line. The real upside landed on the profit line: earnings before interest, taxes, depreciation and amortization adjusted for special items jumped to €4.453 billion, well above the €3.93 billion consensus forecast. Adjusted earnings per share came in at €2.71, also comfortably ahead of analyst estimates.

Crop Science delivered the heaviest lifting. The agricultural unit generated sales of €7.558 billion, an underlying increase of 6.8 percent, partly boosted by a €448 million contribution from the settlement of a licensing dispute with Corteva in North America. Segment EBITDA before special items climbed to €3.014 billion, pushing the margin to 39.9 percent — a sharp year-on-year improvement. Not every product line sparkled: corn seed advanced 7.1 percent, but herbicide sales fell 10.2 percent, with glyphosate-based products dropping even more sharply.

That operational strength, however, is being drowned out by the legal cash drain. Free cash flow swung to minus €2.32 billion, with net outflows of €2.002 billion attributable to payments resolving PCB and glyphosate lawsuits. The effect on the balance sheet was immediate: net debt rose 9 percent from year-end to €32.518 billion, although it remains below the level of a year earlier. Management is sticking to its full-year outlook for free cash flow in a range of minus €2.5 billion to minus €1.5 billion, a bracket that still assumes roughly €5 billion in legal disbursements.

The coming weeks will be decisive. On June 4, the opt-out window closes for the Roundup class-action settlement announced in February. At the same time, the U.S. Supreme Court is expected to issue a ruling in the case of John Durnell, a pre-emption question that could cap future liability if decided in Bayer’s favor. A negative outcome would open the door to fresh waves of litigation. Separately, court approval of the settlement itself is anticipated in July. UBS analyst Matthew Weston, who rates the stock a “buy” with a €52 target, slightly raised his earnings forecast after the results, pointing to the higher profitability in agrochemicals.

Beyond the courtroom, Bayer is pressing ahead with a deep reorganization. Management positions have been cut by two-thirds and six layers of hierarchy eliminated, with the company targeting sustainable annual savings of €2 billion by the end of 2026. The restructuring is designed to create the financial headroom needed to service debt while investing in growth.

Pharma also offers a potential catalyst. The stroke candidate Asundexian is under accelerated review by China’s health regulator and has already secured FDA fast-track status in the United States. Morgan Stanley estimates peak sales potential of up to €4 billion. On trade policy, Bayer expects no material impact from U.S. tariffs this year: the 15 percent levy under the EU-U.S. trade agreement is not set to take effect until late September.

The stock closed at €37.95 on Friday, inching down from the previous day’s €38.09. Year-to-date the shares have moved almost sideways, yet they have surged 65.79 percent over the past twelve months — a reflection of investor hope that operational progress will eventually outweigh legal overhang. With two major legal milestones packed into June and July, the bond between earnings strength and cash flow pain will either loosen or tighten in the months ahead.